ATLAS-1 Study to Develop Predictive Models for Treatment Response in Adults with Depressed Mood Using Esketamine, Conventional TMS, or SAINT

What this Trial Is About

Researchers are evaluating the feasibility and usefulness of creating predictive models to determine how patients with depressed mood might respond to different treatments. This study focuses on using real-world clinical data to support personalized treatment decisions for depression. It will include patients treated with esketamine, conventional transcranial magnetic stimulation TMS, or Stanford Accelerated Intelligent Neuromodulation Therapy SAINT. Existing clinical and research data may also be used to help develop and validate these models. Participants will be grouped based on the treatment they receive as part of their usual care esketamine, conventional repetitive TMS, or SAINT. The study will observe these treatments without altering standard care. Retrospective data may be included to enhance the studys findings. This observational study does not involve assigning treatments but monitors outcomes under normal clinical conditions. During the study, participants will complete the Patient Health Questionnaire 9-item PHQ-9 before treatment, immediately after treatment, two weeks post-treatment, and monthly for up to 12 months. Researchers will collect and analyze clinical data to develop tools that could help predict treatment response. The study runs until March 2037, allowing long-term follow-up and evaluation of treatment outcomes over time.

ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1